prednisone has been researched along with cabozantinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, A; Bögemann, M; Cruciani, G; De Bono, J; De Giorgi, U; De Wit, R; Feyerabend, S; Fizazi, K; Hessel, C; Hoelzer, W; Houédé, N; Hussain, S; Krainer, M; Lam, E; Le Moulec, S; Mainwaring, P; Miller, K; Oudard, S; Polikoff, J; Ramies, D; Saad, F; Smith, M; Stenzl, A; Sternberg, C; Thiery-Vuillemin, A; Weitzman, A | 1 |
| Antonarakis, ES; Basch, EM; Bennett, AV; Chi, KN; Dayan, E; de Bono, JS; de Souza, P; Dreicer, R; Dueck, AC; George, S; Holland, J; Hutson, TE; Kalebasty, AR; Mangeshkar, M; Marx, G; O'Sullivan, JM; Scher, HI; Scholz, M; Schwarz, JK; Vaishampayan, U; Vogelzang, N; Weitzman, AL | 1 |
| Al Harthy, M; Arlen, PM; Bilusic, M; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Hankin, A; Karzai, FH; Kim, JW; Lee, MJ; Lee, S; Madan, RA; Marte, JL; Owens, H; Peer, CJ; Petrylak, DP; Rosner, I; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB; Williams, M; Yuno, A | 1 |
3 trial(s) available for prednisone and cabozantinib
| Article | Year |
|---|---|
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyridines; Survival Rate | 2016 |
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Topics: Aged; Analgesics; Anilides; Bone Neoplasms; Cancer Pain; Double-Blind Method; Drug Combinations; Humans; Male; Middle Aged; Mitoxantrone; Pain Management; Pain Measurement; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyridines | 2019 |
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Treatment Outcome | 2021 |